Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin in Advanced Ovarian Cancer
NCT00050414Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Oct 2002
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in ovarian cancer, sponsored by Johnson & Johnson. Primary endpoint: Objective Response Rate. Started Oct 2002; status: completed.
02
Drugs
trabectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00050414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050414.